comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 03:41:03 - browse：37451

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Takeda, Janssen join wearable maker to measure scratching

focus

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

EU fines Illumina $475 million over Grail acquisition

Superbugs, antibiotic resistance get scrutiny in congress

The EPA's new lead rule: How one expert crunched the numbers

Diagnostic tests are hitting their mathematical limits

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

focus

comprehensive

Wikipedia

Drug repurposing or repositioning? The language matters

Diagnostic tests are hitting their mathematical limits

State Dept. review finds Biden bears some blame for Afghanistan failures

U.K. Biobank has 500,000 peoples' genome sequences available

How one medical school became remarkably diverse

Pediatric cancer treatments threatened by a new FDA policy

Sports medicine is finally prioritizing gender equality

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

The cancer drug shortage isn’t new — and neither are the solutions

Diagnostic tests are hitting their mathematical limits

entertainment

BIO selects John Crowley as new CEO

How to pay for weight loss drugs and save Medicare

CDC director unscathed in first congressional testimony

FDA investigates CAR

Companies helping big Covid

Superbugs, antibiotic resistance get scrutiny in congress

focus

focus

entertainment

Wikipedia